Polycyclo Ring System Patents (Class 514/753)
  • Patent number: 11826578
    Abstract: The present invention relates to a method for producing a nitrogen-based non-thermal atmospheric pressure plasma for treating damaged muscles or promoting regeneration of damaged muscles, and to a method for treating damaged muscle or promoting regeneration of damaged muscles using the atmospheric pressure plasma. The nitrogen-based non-thermal atmospheric pressure plasma according to the present invention can effectively induce muscle cell activation, migration of muscle cells to damaged sites, muscle cell proliferation, and muscle cell differentiation, without surgical operation or during a treatment procedure after surgical operation, and thus can be advantageously used as a novel therapeutic agent and therapeutic method against muscle damage and muscle damage-associated diseases.
    Type: Grant
    Filed: December 22, 2021
    Date of Patent: November 28, 2023
    Inventors: Chul Ho Kim, Sung Un Kang, Jae Won Choi
  • Publication number: 20150079111
    Abstract: Mechanisms for complications of renal failure and processes for treating the same are disclosed. They include contacting a biological fluid (e.g. blood) with a filter body, the filter body having immobilized thereon either a CD36 receptor or a CD36 receptor fragment or a SCARB1 receptor or a SCARB1 receptor fragment, the blood having a reduced quantity of oxidatively modified proteins after contacting the filter body. They also include administering an antagonist drug to a patient that blocks the binding activity of the RAGE receptor or the CD36 receptor or the SCARB1 receptor. Diagnostic methods are also provided.
    Type: Application
    Filed: June 5, 2013
    Publication date: March 19, 2015
    Inventor: Jonas AXELSSON
  • Publication number: 20150030583
    Abstract: The discovery of clonally pure populations of serosal cancer stem cells (CSCs) as well as methods of producing CSCs, culturing the CSCs and using them in screening assays, has lead to the development of methods of treating serosal and ovarian cancers by targeting removal or inhibition of the glycocalyx coat surrounding such cells, and includes combination therapies using particular chemotherapeutics in conjunction with glycocalyx inhibitors, as well as the same new chemotherapy treatments without targeting the glycocalyx, where the chemotherapeutic agent is any one of LBH-589 (Panobinostat), NVP-AUY922, LAQ824 (NVP-LAQ824, Dacinostat), colchicine, brefeldin A, diphenyleneiodonium chloride, any combination thereof or another agent identified herein. These treatment methods of the invention can also be used in combination with radiation treatment or other conventional cancer therapy.
    Type: Application
    Filed: March 30, 2012
    Publication date: January 29, 2015
    Applicant: SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: Malcolm A.S. Moore, Server A. Ertem
  • Publication number: 20140243404
    Abstract: This disclosure is related to halonium compounds useful for cyclization of polyenes, alkenoic acids, and alkenyl alkyl ethers, and halogenation of aromatic compounds. The synthesis of such halonium compounds, compounds made using such halonium compounds, and synthesis of natural compounds, including decalins, using the halonium compounds is also disclosed.
    Type: Application
    Filed: September 13, 2011
    Publication date: August 28, 2014
    Applicant: The Trustees of Columbia University in the City of New York
    Inventors: Scott Alan Snyder, Daniel S. Treitler, Alexandria P. Brucks, Andreas Gollner, Maria I. Chiriac, Nathan E. Wright, Jason J. Pflueger, Steven P. Breazzano
  • Publication number: 20140199320
    Abstract: The invention provides inhibitors capable of binding to a member of the inflammasome group comprised of IL-1?, IL-1 receptor type 1, NLRP3, ASC, Caspase-1 and cathepsin B with a dissociation constant of 10-8 mol/l or smaller for the prevention and treatment of acne, specifically an antibody, an antibody fragment, an antibody-like molecule, an oligopeptide of 6 to 30 amino acid residues, a nucleic acid aptamer molecule of 10 to 75 nucleotides in length or a soluble polypeptide comprising a contiguous amino acid sequence of at least 30 amino acids comprised within the protein sequence of a member of the group comprised of IL-1?, IL-1 receptor type 1, IL-1 receptor type 2, NLRP3, ASC and Caspase-1. Similarly, an interfering RNA or an antisense modulator of gene expression of IL-1?, I L-1? receptor type 1, NLRP3, ASC, Caspase-1 and cathepsin B are provided for the prevention or treatment of acne.
    Type: Application
    Filed: July 11, 2012
    Publication date: July 17, 2014
    Applicant: UNIVERSITAT ZURICH
    Inventors: Dragana Jankovic, Magdalena Kistowiska, Emmanuel Contassot, Lars E. French, Samuel Gehrke
  • Publication number: 20140148398
    Abstract: Compounds useful for the treatment of giardiasis are described.
    Type: Application
    Filed: October 12, 2011
    Publication date: May 29, 2014
    Applicants: The United States of America, as represented by the Secretary, Dept. of Health and Human Service, UNIVERSITY OF MARYLAND, COLLEGE PARK
    Inventors: Wei Zheng, Catherine Chen, Juan Jose Marugan, Noel Southall, Christopher P. Austin, Andrey Galkin, Liudmila Kulakova, Osnat Herzberg
  • Publication number: 20120039888
    Abstract: The present invention relates to compositions and methods for treating inflammation-associated tissue damage, and particularly transfusion-associated, disorders, by inhibiting or reducing E-selectin mediated signal transduction pathways, such as E-selectin mediated activation of ?M?2.
    Type: Application
    Filed: May 10, 2011
    Publication date: February 16, 2012
    Inventors: Paul Frenette, Andrés Hidalgo
  • Publication number: 20110027384
    Abstract: The present invention provides a photosensitising composition comprising a mixture of at least one oxygen carrier, at least one oxidising agent and at least one surfactant, and its uses. The ratio of the at least one oxygen carrier to the at least one oxidising agent to the at least one surfactant may be in the range of 50:40:10 to 80:19.8:0.2. The photosensitising composition may be used for treating and/or preventing conditions caused by microorganisms.
    Type: Application
    Filed: April 6, 2009
    Publication date: February 3, 2011
    Applicant: National University of Singapore
    Inventors: Anil Kishen, Saji George
  • Patent number: 7618988
    Abstract: Compounds of formula I in which R has a meaning as indicated in claim 1, or one of their optical isomers or pharmaceutically acceptable salts, used for the treatment of extrapyramidal movement disorders and/or adverse effects in extrapyramidal movement disorders and/or for the treatment of extrapyramidal symptoms (EPS) induced by neuroleptics.
    Type: Grant
    Filed: August 12, 2002
    Date of Patent: November 17, 2009
    Assignee: Merck Patentgesellschaft
    Inventors: Henning Böttcher, Ralf Devant, Maria Devant, legal representative, Gerd Bartoszyk, Hermann Russ, Frank Weber, Christoph Seyfried
  • Publication number: 20090149445
    Abstract: The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation comprising administering to a patient in need thereof an effective amount of a compound of the formula: or a pharmaceutically acceptable salt thereof. In addition, the present invention provides novel pharmaceutical compounds of Formula I, including the pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions which comprise as an active ingredient a compound of Formula I.
    Type: Application
    Filed: July 15, 2008
    Publication date: June 11, 2009
    Inventors: Michael Joseph Coghlan, Jonathan Edward Green, Timothy Alan Grese, Prabhakar Kondaji Jadhav, Donald Paul Matthews, Mitchell Irvin Steinberg, Kevin Robert Fales, Michael Gregory Bell
  • Publication number: 20090105260
    Abstract: An IR spectroscopic technique provides methods for measuring the irritation potential of a formulation and to assess the ability of molecules to enhance the permeability of substances into and through skin using samples comprising stratum corneum. Molecules are screened for their performance as chemical penetration enhancers using a unique in silico procedure that may be applied iteratively in an attempt to generate molecules showing successively higher performance. Both the irritation potential and the ability of the molecule to enhance penetration are considered in the in silico approach. The invention provides specific molecules that may be used in topical or transdermal formulations to improve the delivery of actives. The structures of compounds of the invention include: Formulas (I), (II), (III), (IV), (V), (IV) and analogs thereof.
    Type: Application
    Filed: January 17, 2006
    Publication date: April 23, 2009
    Inventors: Samir Mitragotri, Pankaj Karande, Amit K. Jain
  • Patent number: 7378449
    Abstract: An additive mixture useful as a flame retardant is described. The mixture is comprised of (i) a poly(bromophenyl)alkane having in the molecule in the range of 13 to 60 carbon atoms and in the range of two to four aryl groups and (ii) a poly(bromophenyl)bromoalkane having in the molecule in the range of 13 to 60 carbon atoms and in the range of two to four aryl groups, said poly(bromophenyl)bromoalkane being in an amount which is greater than 25 wt %, based on the total weight of the additive mixture. A facile process for making the poly(bromophenyl)bromoalkane is also described.
    Type: Grant
    Filed: October 23, 2006
    Date of Patent: May 27, 2008
    Assignee: Albemarle Corporation
    Inventors: Raymond B. Dawson, Saadat Hussain
  • Publication number: 20070292493
    Abstract: The present invention relates to a method and transdermal pharmaceutical composition for preventing or reducing the likelihood of calcium deficiency or imbalances caused by calcium deficiency. The transdermal pharmaceutical composition includes a therapeutically effective amount of a pharmaceutically acceptable salt of calcium and a pharmaceutically acceptable carrier constituting a pluronic lecithin organogel.
    Type: Application
    Filed: June 15, 2006
    Publication date: December 20, 2007
    Inventor: Barbara T. Brierre
  • Patent number: 6967102
    Abstract: The present invention is directed to methods, pharmaceutical compositions and kits for modulating skeletal muscle precursor cell activation. Modulation is effected through the use of nitric oxide (NO), donors of NO, inhibitors of NO activity (NO inhibitor) or regulators of NO production, either locally or systemically. The invention further teaches the use of NO, an NO donor, an NO inhibitor or a regulator of NO production to modulate the effects of steroid hormone on skeletal muscle. The invention further provides a method for identifying a compound which effects a change in activation state of muscle precursor cells. A number of advantages is evident. By allowing skeletal muscle precursor cells to be manipulated directly, the invention enables specific treatments to regenerate and repair muscle.
    Type: Grant
    Filed: March 10, 2000
    Date of Patent: November 22, 2005
    Assignee: University of Manitoba
    Inventor: Judy E. Anderson
  • Patent number: 6743825
    Abstract: An additive mixture useful as a flame retardant is described. The mixture is comprised of (i) a poly(bromophenyl)alkane having in the molecule in the range of 13 to 60 carbon atoms and in the range of two to four aryl groups and (ii) a poly(bromophenyl)bromoalkane having in the molecule in the range of 13 to 60 carbon atoms and in the range of two to four aryl groups, said poly(bromophenyl)bromoalkane being in an amount which is greater than 25 wt %, based on the total weight of the additive mixture. A facile process for making the poly(bromophenyl)bromoalkane is also described.
    Type: Grant
    Filed: August 5, 2002
    Date of Patent: June 1, 2004
    Assignee: Albemarle Corporation
    Inventors: Raymond B. Dawson, Saadat Hussain
  • Patent number: 6291534
    Abstract: In the literature, a correlation between the inhibition of 5-lipoxygenase and anti-inflammatory and immunomodulatory activity sufficient to effectively treat psoriasis, is known. It seems that, in particular, the excellent results can be obtained with lonapalene (6-chloro-2,3-dimethoxynaphthalendioldiacetate). However, the clinical use of lonapalene has not been successful most likely due to the significant number of side effects. With these considerations, after various studies, we have identified a molecule which we have patented with the name of endipalene, which seems to guarantee notable therapeutic results without side effects.
    Type: Grant
    Filed: May 25, 2000
    Date of Patent: September 18, 2001
    Inventor: Giorgio Endrici
  • Patent number: 6245782
    Abstract: The present invention pertains to methods for reducing the platelet activation state in an individual comprising administering a selective serotonin reuptake inhibitor (SSRI). The platelet activation state is reduced upon administering a SSRI, as measured by one or more platelet activation markers. The invention also relates to methods for treating or preventing an individual at risk for a vascular event, disease or disorder by administering a SSRI.
    Type: Grant
    Filed: May 17, 1999
    Date of Patent: June 12, 2001
    Assignee: Heartdrug Research L.L.C.
    Inventors: Victor L. Serebruany, Paul A. Gurbel, Christopher M. O'Connor
  • Patent number: 5859068
    Abstract: A method for the acceleration of tissue growth using continuous fluorocarbon liquid-based positive pressure is disclosed, whereby significant increase in tissue growth is achieved.
    Type: Grant
    Filed: February 24, 1995
    Date of Patent: January 12, 1999
    Assignee: Children's Medical Center Corporation
    Inventor: Jay M. Wilson
  • Patent number: 5856272
    Abstract: A novel algaecide composition and method of removing algae from a variety of surfaces, in particular a composition comprising at least one terpene and at least one algaecidal agent, is disclosed.
    Type: Grant
    Filed: November 13, 1995
    Date of Patent: January 5, 1999
    Inventor: Joe S. Wilkins, Jr.
  • Patent number: 5834521
    Abstract: Tetracyclic compounds having the following structure are described: ##STR1## wherein R.sub.1 -R.sub.10 are as defined. The tetracyclic compounds are capable of potent effects on steroid sensitive tissues and have demonstrated increased uterine weight, antiovulatory effects and potent steroid receptor binding. The compounds have therapeutic utility in reproductive applications such as fertility control, labor induction, ovulation induction and spermatogenesis. Methods for preparing the tetracyclic compounds from substituted indanones are also described.
    Type: Grant
    Filed: August 5, 1996
    Date of Patent: November 10, 1998
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: John H. Dodd, Lisa A. Dixon, James L. Bullington, Charles F. Schwender
  • Patent number: 5824703
    Abstract: A method of assisting a mammal having a lung disorder to breathe ambient gas normally, i.e., without the assistance of a ventilator. The method includes providing an animal having a lung disorder, such as surfactant deficiency, stiff lung, or hyperinflated lung syndrome, and instilling a minimum effective dose of a perfluorochemical liquid or emulsion through the trachea for coating the alveolar sacs of a lung of the mammal. The preferred perfluorochemicals have a very low vapor pressure to avoid inducing hyperinflated lung syndrome and are supplied in a minimum effective dosage sufficient to coat the inner lung surfaces. The perfluorochemicals are permeable to the ambient gas and reside substantially permanently within the alveolar sacs without inducing hyperinflated lung syndrome. The liquid is instilled in an amount sufficient to enable the animal to breathe the ambient gas normally with O.sub.2 /CO.sub.2 blood gas exchange. Effective coating of the lungs with a small (generally <0.
    Type: Grant
    Filed: December 27, 1996
    Date of Patent: October 20, 1998
    Assignee: Synthetic Blood International, Inc.
    Inventor: Leland C. Clark, Jr.
  • Patent number: 5543298
    Abstract: The method for assaying the SOD (super oxide dismutase) activity in liquid medium is based on the activation of self-oxidization, by SOD activity, of a reactive agent having the general formula (I) wherein either n is 1 or 2, R.sup.1 is --OR.sup.4 or --NR.sup.5 R.sup.6 ; R.sup.2 is H, --OR.sup.4, alkyl (1-6C), --CH.sub.2 -- or --CH.sub.2 --CH.sub.2 --, to form a ring by binding to the phenyl substituent, at meta with respect to R.sup.1 ; and R.sup.3 is H, alkyl (1-6C) or --OR.sup.4 (if R.sup.2 is different from --OR.sup.4); with R.sup.4 being H or alkyl (1-6C); R.sup.5 being H, alkyl (1-6C), --CH.sub.2 COOH, --C.sub.6 H.sub.5 COOH or --C.sub.6 H.sub.5 SO.sub.3 H; and R.sup.6 is H, alkyl (1-6C) or --CH.sub.2 COOH; or n is 1, R.sup.1 is --OR.sup.4, R.sup.2 is --CH.sub.2 --O--, in order to form a ring by bonding of O with the phenyl substituent, at meta with respect to R.sup.1 ; and R.sup.3 is H or --OR.sup.4.
    Type: Grant
    Filed: June 6, 1994
    Date of Patent: August 6, 1996
    Assignee: Oxis International S.A.
    Inventors: Jinzhu Xu, Jean-Claude Y. Yadan, Marc E. Moutet, Jean R. Chaudiere
  • Patent number: 4803067
    Abstract: Compositions for cosmetics and dermatology comprising a perfluoropolyether liquid dispersed in an oil/water or water/oil emulsion, or in a solid phase suited to form a gel, suspended in an organic liquid phase.
    Type: Grant
    Filed: March 26, 1986
    Date of Patent: February 7, 1989
    Assignee: Ausimont S.p.A.
    Inventors: Fabio Brunetta, Stefano Bader, Giovanni Pantini
  • Patent number: 4769241
    Abstract: Perfluorocarbon emulsion formulations are oxygenated prior to use by means of a portable oxygenation system. The blood substitute is in a closed container or bag. An oxygen-containing gas is introduced into the bag from a separate container. The bag is continuously agitated for a sufficient time to increase the pO.sub.2 of the perfluorocarbon emulsion formulations to a desired pressure, e.g., to at least 600 mmHg. In one embodiment, the system used for oxygenation of the perfluorocarbon emulsion formulations comprises a small tank for gas having an inlet port and an outlet port fitted with shut-off valves. The outlet port is adapted to be connected to a filter which, in turn, is adapted to be connected to the inlet port of a three-way valve. The primary outlet of the three-way valve is adapted to mount a hypodermic needle which is adapted to be pushed through a rubber septum in a port of the bag to communicate with the interior of the bag.
    Type: Grant
    Filed: September 23, 1986
    Date of Patent: September 6, 1988
    Assignee: Alpha Therapeutic Corporation
    Inventors: Charles M. Heldebrant, Kim C. Crowe, George R. Groveman, Charles H. Davis, Jr.
  • Patent number: RE44704
    Abstract: The present invention is based on the discovery that the administration of at least one immunoconjugate and at least one chemotherapeutic agent provides an unexpectedly superior treatment for cancer. The present invention is directed to compositions comprising at least one immunoconjugate and at least one chemotherapeutic agent and to methods of treating cancer using at least one immunoconjugate and at least one chemotherapeutic agent. The present invention also provides methods of modulating the growth of selected cell populations, such as cancer cells, by administering a therapeutically effective amount of at least one chemotherapeutic agent and at least one immunoconjugate.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: January 14, 2014
    Assignee: Immunogen Inc.
    Inventors: Ravi V. J. Chari, Walter A. Blättler